BioBots Introduces its Production Desktop 3D Printer for Living Tissue
BOSTON, MA: BioBots, a startup founded at University of Pennsylvania has announced the debut of its first production desktop 3D printer, capable of printing functional 3D constructs from living cells.
The product was launched after nine months of beta testingpartnership with researchers at major tissue and biomedical engineering institutions across the world.The printer’s compact design, easy operation and intuitive open cartridge system, allows its users to purchase pre-prepared bioinks kits common tissue types, upon which living cells can be added directly. BioBots empowers the researchers to design and utilize their own materials, of which dozens of formulations, both natural and synthetic, have already been tested on the system.
The printer is easy to use and researchers from around the world could use it without much technical knowledge about its technology and thus lowering the cost required to operate the device.
Starting with its beta community earlier this year, the company aims to pair its accessible technology model with a growing global network of researchers and clinicians to foster an open dialog around tissue engineering research and development. Using its beta version, researchers from universities like Stanford, Penn, MIT and Drexel have already created bone, liver and brain tissues from living human cells, and the company hopes the greater reach of BioBot 1 will fuel an even more massive wave of innovation in future.
Being a new technology, bioprinting devices like the BioBot 1 have the potential to aid researchers greatly in understanding cancer detection and other pathologies, along with the ability to replicate and study biological structures built out of a patient’s own cells. Bioprinting can significantly reduce the length of drug testing cycles, and even enable personalized treatment programs for complex diseases discovered for the first time in medical history. While simple bioprinted tissues and organs have already seen transplantation in patients, the historically limited access to these devices has restricted innovation to large, well-funded institutions with large teams of highly specialized researchers. Greater access to this technology through ease of use desktop models like BioBot 1, and the collaborative community around bioprinting research that BioBots has created, is expected to promote this development.